Feasibility Assessment for a Specialized Oncology Center in Emerging Urban Hubs

Executive Viability Abstract

This feasibility study evaluates the establishment of a 50-bed specialized oncology center in the Lekki-Epe corridor of Lagos, Nigeria. With a projected IRR of 32.4% and a payback period of 4.2 years, the project leverages a $450M addressable market currently underserved by existing infrastructure. Key success factors include high-end radiotherapy integration and a hybrid energy model to mitigate local utility costs.

## Executive Feasibility Thesis The oncology landscape in emerging urban hubs, specifically Lagos, is characterized by a significant supply-demand imbalance. Nigeria records approximately 124,000 new cancer cases annually, yet fewer than 10 functional linear accelerators serve a population of 200 million. This project targets the 'missing middle' and HNI (High Net Worth Individual) segments who currently spend over $1B annually on medical tourism to India and the UAE. The thesis rests on providing 'Tier-1' oncology care locally at 60% of the cost of international alternatives, capturing a local market share of 12% within the primary catchment area. ### Core Assumptions * **Local Market Size:** 18,500 treatable patients within a 50km radius of the Lekki-Epe corridor. * **Cost of Capital (WACC):** 18% (reflecting a 24% cost of equity and 12% cost of debt in local USD-indexed terms). * **Capacity Utilization:** Year 1: 35%; Year 2: 55%; Year 3 onwards: 75%. * **Patient Yield:** Average revenue per patient (ARPP) of $4,800 for full-cycle radiotherapy and chemotherapy. ## Technical Feasibility & Operational Specifications The facility will occupy 3,500 square meters, designed with specialized radiation shielding (2-meter thick high-density concrete bunkers). * **Imaging Suite:** 1x Digital PET-CT (Siemens/GE) for precise staging, 1x 1.5T MRI for soft tissue definition. * **Radiotherapy Unit:** 2x Linear Accelerators (LINAC) with VMAT and IGRT capabilities to minimize side effects. * **Chemotherapy Daycare:** 15-bay infusion center with a certified cytotoxic compounding pharmacy (ISO Class 5 cleanroom). * **Digital Backbone:** Cloud-native HIS/RIS/PACS system for remote Dosimetry planning, allowing international collaboration with oncologists in London or Mumbai. ## Detailed Capital Expenditure (Capex) | Item | Unit Cost (USD) | Qty | Total (USD) | Reasoning | | :--- | :--- | :--- | :--- | :--- | | **Medical Equipment - LINAC** | $3,200,000 | 2 | $6,400,000 | Core therapeutic revenue driver. | | **PET-CT Scanner** | $1,800,000 | 1 | $1,800,000 | Essential for metabolic staging and recurrence monitoring. | | **Civil Construction** | $1,250 /sqm | 3,500 | $4,375,000 | Specialized oncology hospital build-out including bunkers. | | **Hybrid Energy System** | $450,000 | 1 | $450,000 | 500kVA Solar/Diesel hybrid to ensure zero downtime for LINAC. | | **Furniture & Fixtures** | $250,000 | 1 | $250,000 | Hospital-grade antimicrobial furniture. | | **Pre-operative Interest** | $650,000 | 1 | $650,000 | Interest capitalized during 18-month construction. | | **Total Initial Capex** | | | **$13,925,000** | | ## Realistic Operating Expenditure (Opex) * **Clinical Staffing:** $180,000/month. (Lead Oncologists @ $15k, Physicists @ $8k, Specialized Nurses @ $1.5k). Based on a 70-person clinical team. * **Equipment Maintenance (AMC):** $51,000/month. Calculated at 6% of hardware value annually after Year 1 warranty. * **Consumables & Reagents:** $85,000/month. Includes chemo drugs, isotopes (FDG-18), and specialized catheters. * **Utility & Power:** $28,000/month. High consumption for cooling superconducting magnets and LINAC systems, factoring in local diesel price volatility ($1.10/liter). * **Marketing & Referral Management:** $15,000/month. Focused on GP education programs and diagnostic lab partnerships. ## Financial Model & Sensitivity Range on ROI/IRR The project assumes a 10-year terminal value with a 5% exit cap rate. * **Base Case:** 32.4% IRR. Assumes $4,800 ARPP and 75% peak utilization. * **Optimistic Case (High Yield):** 41.2% IRR. Assumes $5,500 ARPP through premium private room upgrades and 85% utilization due to faster-than-expected referral uptake. * **Pessimistic Case (Market Compression):** 19.5% IRR. Assumes 20% reduction in patient volume due to regional economic downturn and a 15% increase in Opex via currency devaluation impacting imported consumables. **Payback Period:** 4.2 Years (Base Case). **Net Present Value (NPV):** $18.4M at 18% Discount Rate. ## Regulatory & Environmental Compliance Frameworks Operating in Nigeria requires adherence to both health and nuclear safety standards: * **NNRA (Nigerian Nuclear Regulatory Authority):** Strict licensing required for importing and operating radioactive sources/LINACs. Requires quarterly dosimetry audits for staff. * **HEFAMAA (Health Facilities Monitoring and Accreditation Agency):** Local Lagos State certification for specialty surgical and clinical centers. * **EIA (Environmental Impact Assessment):** Focus on biomedical waste management, specifically the disposal of cytotoxic waste via high-temperature incineration (minimum 1,200°C) to prevent local groundwater contamination. ## Strategic Takeaways 1. **First-Mover Advantage:** The absence of private comprehensive oncology centers in the Lekki corridor provides a window to capture the premium market. 2. **Financial Resilience:** The high IRR is driven by the 'medical tourism arbitrage'—charging significantly less than foreign hospitals while maintaining high margins due to local labor cost efficiencies. 3. **Risk Mitigation:** Power instability remains the highest technical risk; the inclusion of a dedicated microgrid in Capex is non-negotiable for equipment longevity.